Analyst Research

Report Title Price
Provider: GlobalData
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: Wright Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioInvent International AB Presents Positive Data for BI-505 at International Myeloma Congress

Thursday, 4 Apr 2013 02:30am EDT 

BioInvent International AB announced that the previously communicated positive results from a phase I trial of BI-505 is presented on April 4, 2013 at The International Myeloma Workshop in Kyoto, Japan. At the same meeting, preclinical data is also presented which demonstrate significantly enhanced efficacy when approved myeloma drugs are combined with BI-505. BI-505 is a human antibody directed against ICAM-1 and is developed for the treatment of multiple myeloma. The preliminary analysis shows that BI-505 has an advantageous safety profile. In cohorts where extended treatment was available, 24% of the patients had stable disease for at least two months, indicating effect of BI-505. At the same meeting, new preclinical data is also presented showing significantly enhanced anti-myeloma activity when the approved drugs Velcade or Revlimid is combined with BI-505 compared to single agent treatment. Combined treatment was evaluated in two different experimental models and the drugs were given in a similar way as to patients with myeloma. In one of the models enhanced survival was observed following combination therapy with BI-505, compared to single agent treatment with the approved drugs. In the second model, complete remission was observed in the majority of animals when combining BI-505 with Revlimid or Velcade. 

Company Quote

0.02 +0.68%
11 Jul 2014